logo
Book a meeting
MILLENDO THERAPEUTICS

Millendo Therapeutics

Biotechnology, 7000 Shoreline Ct, Ann Arbor, Michigan, 94080, United States, 11-50 Employees

millendo.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: +17*********

Who is MILLENDO THERAPEUTICS

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatm...

Read More

lock icon Get Full Access
map
  • 7000 Shoreline Ct, Ann Arbor, Michigan, 94080, United States Headquarters: 7000 Shoreline Ct, Ann Arbor, Michigan, 94080, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from MILLENDO THERAPEUTICS

MILLENDO THERAPEUTICS Org Chart and Mapping

Employees
Nancy Skurka

Nancy Skurka

Clinical Trial Associate

Eric Henricks

Eric Henricks

Manager, Clinical Operations

See Full Org Chart arrow
email-formate-icon
View Email Formats for MILLENDO THERAPEUTICS
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding MILLENDO THERAPEUTICS

Answer: MILLENDO THERAPEUTICS's headquarters are located at 7000 Shoreline Ct, Ann Arbor, Michigan, 94080, United States

Answer: MILLENDO THERAPEUTICS's phone number is +17*********

Answer: MILLENDO THERAPEUTICS's official website is https://millendo.com

Answer: MILLENDO THERAPEUTICS's revenue is $10 Million to $25 Million

Answer: MILLENDO THERAPEUTICS's SIC: 2834

Answer: MILLENDO THERAPEUTICS has 11-50 employees

Answer: MILLENDO THERAPEUTICS is in Biotechnology

Answer: MILLENDO THERAPEUTICS contact info: Phone number: +17********* Website: https://millendo.com

Answer: Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushings Syndrome (CS).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access